Sanofi

Centre National De La Recherche Scientifique

C M Industries

Sanofi (societe Anonyme)

Pierre Gros

Franz K Jansen

Pierre Casellas

Bernard Bourrie

Emilio Crisafulli

Bernard Pau

Jean Duheille

Guy Mazue

Guy Voisin

Prolonged-action immunotoxin consisting of a conjugate in which an antibody or antibody fragment is coupled, by means of a covalent structure containing a disulfide group or a thioether group, with a glycoprotein which inactivates ribosomes and has a prolonged action obtained by the oxidation of its saccharide units which periodate ions.

Prolonged-action immunotoxins containing a glycopeptide constituent

The present invention relates to conjugates in which a monovalent carboxylic ionophore is associated by means of a covalent bond with a macromolecule chosen from antibodies, fragments of antibodies, proteins such as peptide hormones or human proteins, and peptide ligands. It also relates to the activated inophores. These conjugates are suitable as immunotoxin potentiators.

Conjugates in which a monovalent carboxylic ionophore is associated by

Immunotoxins formed by the covalent coupling of, on the one hand, the A chain of ricin, as such or correctly modified, with, on the other hand, an antibody or a fragment of an antibody, used in its natural form or correctly modified, which possesses the capacity to selectively recognize an antigen carried by the intended target cells. The coupling is effected either via a disulfide bond or via a thioether bond, with the limitation that, when the coupling is effected via a disulfide and one of the sulfur atoms is that belonging to the A chain of ricin, the other sulfur is bonded to the antibody by a spacing structure which is itself bonded to a group of the protein other than an amine group.

Cytotoxic conjugates which can be used in therapy and process for their

The present invention relates to conjugates in which a monovalent carboxylic ionophore is associated by means of a covalent bond with a macromolecule chosen from antibodies, fragments of antibodies, proteins such as peptide hormones or human proteins, and peptide ligands. It also relates to the activated ionophores. These conjugates are suitable as immunotoxin potentiators.

The present invention relates to conjugates in which a monovalent carboxylic ionophore is associated by means of a covalent bond with a macromolecule chosen from antibodies, fragments of antibodies, and peptide ligands. It also relates to the activated ionophores. These conjugates are suitable as immunotoxin potentiators.

The present invention relates to a process for potentiating the activity of a conjugate consisting of the A chain of ricin coupled with an antibody directed against human T cells, the said process consisting in adding an effective quality of ammonium chloride to the said conjugate.

Process for the potentiation of immunotoxins

The invention relates to a cytotoxic pharmaceutical combination comprising:

Appropriate cytotoxic pharmaceutical combination especially for the

The invention relates to the 2-aminoalkyl-9-hydroxyellipticinium chloride hydrochloride of formula: ##STR1## in which Z represents hydrogen or a lower alkyl group, Alk represents a lower alkylene group and Am represents a di(lower alkyl)amino, pyrrolidino or piperidino group. These compounds are useful as antitumour agents.

Hydrochlorides of chlorides of 2-aminoalkyl-9-hydroxy-ellipticinium

The present invention relates to drugs characterized in that they comprise, in association, at least one immunotoxin and at least one monovalent carboxylic ionophore.

Drugs comprising in association at least one immunotoxin and at least

The present invention relates to new immunoenzymic conjugates resulting from a chemical coupling, by covalent bond, of an antibody or a fragment of antibody, which has retained the capacity of recognizing the selected antigen, with an enzyme capable of producing ammonium ions from natural substrates which are well tolerated in higher animal organisms. The invention also relates to a process for the preparation of these conjugates and the medicinal associations of said conjugates with an immunotoxin.

New conjugates associating, by covalent bond, an enzyme with an

The invention relates to pharmaceutical compositions comprising a combination of at least one immunotoxin and at least one mannose-containing polymer. This combination makes it possible to inhibit the rapid elimination of immunotoxins from the plasma after injection.

Pharmaceutical composition comprising a combination of at least one

The present invention relates to polyfunctional hydrophilic spherical microparticles of uniform size which contain from 5 to 95% of units originating from the copolymerization of an aldehyde of the formula ##STR1## R.sub.1 being an alkyl radical, from 5 to 90% of units originating from the copolymerization of an acrylic acid ester of the formula ##STR2## in which R.sub.2 is H or alkyl and R.sub.3 is a hydroxyalkyl group, less than 15% of units originating from an acrylic acid derivative chosen from amongst ##STR3## R.sub.4, R.sub.5 and R.sub.6 being alkyl radicals, and from 0.1 to 10% of units originating from a crosslinking product. The invention also relates to a process for the preparation of the said microparticles and to the use of these microparticles for the nephelometric determination of HB.sub.s antigen.

Nephelometric determination of HB.sub.s antigen with antibody-containing

Imidazolides of the formula: ##STR1## in which: E represents an inert spacing structure; and

Imidazolides as intermediates for the synthesis of cytotoxic conjugates

The present invention relates to an anti-cancer drug, characterized in that it contains at least one product constituted by the chain A of recin conjugated by means of a disulfide bridge with at least one fraction of a monoclonal antibody of leukaemic anti-cell specificity, and to the processes for preparing the active ingredient of said drug.

Growing community of inventors

Montpellier, France

Pierre Gros